105 related articles for article (PubMed ID: 20088751)
1. Thyroid autoimmunity and treatment response to escitalopram in major depression.
Eller T; Metsküla K; Talja I; Maron E; Uibo R; Vasar V
Nord J Psychiatry; 2010 Aug; 64(4):253-7. PubMed ID: 20088751
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
8. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
11. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
12. Anti-thyroid peroxidase antibody and vitiligo: a controlled study.
Daneshpazhooh M; Mostofizadeh G M; Behjati J; Akhyani M; Robati RM
BMC Dermatol; 2006 Mar; 6():3. PubMed ID: 16526964
[TBL] [Abstract][Full Text] [Related]
13. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
15. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
16. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
17. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
19. Association between thyroid autoimmunity and fibromyalgia.
Suk JH; Lee JH; Kim JM
Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):401-4. PubMed ID: 22549342
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]